Rigel Pharmaceuticals (RIGL) Competitors $19.22 -1.32 (-6.45%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. CLDX, NVAX, OPK, GERN, INVA, MYGN, VSTM, EBS, VNDA, and IRWDShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Innoviva (INVA), Myriad Genetics (MYGN), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Celldex Therapeutics Novavax OPKO Health Geron Innoviva Myriad Genetics Verastem Emergent BioSolutions Vanda Pharmaceuticals Ironwood Pharmaceuticals Celldex Therapeutics (NASDAQ:CLDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking. Is CLDX or RIGL more profitable? Rigel Pharmaceuticals has a net margin of 2.46% compared to Celldex Therapeutics' net margin of -1,544.32%. Rigel Pharmaceuticals' return on equity of -14.80% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Rigel Pharmaceuticals 2.46%-14.80%3.03% Does the media refer more to CLDX or RIGL? In the previous week, Celldex Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 7 mentions for Celldex Therapeutics and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat Celldex Therapeutics' score of 0.02 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, CLDX or RIGL? Rigel Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M196.50-$141.43M-$2.45-8.48Rigel Pharmaceuticals$179.28M2.05-$25.09M$0.9421.85 Which has more volatility & risk, CLDX or RIGL? Celldex Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CLDX or RIGL? 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend CLDX or RIGL? Celldex Therapeutics currently has a consensus price target of $54.33, indicating a potential upside of 161.47%. Rigel Pharmaceuticals has a consensus price target of $36.80, indicating a potential upside of 79.16%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Celldex Therapeutics is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the MarketBeat Community believe in CLDX or RIGL? Celldex Therapeutics received 156 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. Likewise, 75.24% of users gave Celldex Therapeutics an outperform vote while only 68.98% of users gave Rigel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes62375.24% Underperform Votes20524.76% Rigel PharmaceuticalsOutperform Votes46768.98% Underperform Votes21031.02% SummaryRigel Pharmaceuticals beats Celldex Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$360.83M$7.13B$5.74B$8.28BDividend YieldN/A2.72%4.55%4.02%P/E Ratio146.727.3324.7119.36Price / Sales2.05239.38396.6593.27Price / CashN/A65.6738.1634.64Price / Book-12.526.787.154.51Net Income-$25.09M$142.41M$3.20B$247.14M7 Day Performance1.03%5.03%2.85%3.64%1 Month Performance-4.47%4.47%7.00%-2.30%1 Year Performance42.64%-3.29%15.59%4.93% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals3.0106 of 5 stars$19.22-6.4%$36.80+91.5%+44.6%$344.04M$179.28M137.58160CLDXCelldex Therapeutics2.2228 of 5 stars$20.35-0.3%$55.38+172.1%-50.5%$1.35B$7.02M-7.92150NVAXNovavax3.7034 of 5 stars$8.38+4.9%$18.00+114.8%+63.6%$1.35B$682.16M-3.711,990Analyst RevisionOPKOPKO Health4.2472 of 5 stars$1.81+4.0%$2.75+51.9%+87.6%$1.22B$713.14M-9.533,930Analyst RevisionGERNGeron4.3265 of 5 stars$1.74+5.8%$5.75+231.4%-47.1%$1.11B$76.99M-5.4270INVAInnoviva4.3148 of 5 stars$17.53+0.8%$55.00+213.7%+14.8%$1.10B$358.71M25.41100Analyst UpgradePositive NewsMYGNMyriad Genetics4.2566 of 5 stars$10.12+0.5%$21.89+116.3%-55.1%$924.05M$837.60M-7.782,700VSTMVerastem3.0959 of 5 stars$7.23+3.9%$13.63+88.5%-42.9%$321.79M$10M-2.2750Earnings ReportAnalyst ForecastNews CoverageEBSEmergent BioSolutions4.1448 of 5 stars$5.78+1.1%$14.33+148.2%+138.0%$313.80M$1.01B-1.411,600Analyst RevisionVNDAVanda Pharmaceuticals4.6069 of 5 stars$5.08+2.0%$16.50+224.8%+23.9%$296.25M$198.77M-15.88290Positive NewsIRWDIronwood Pharmaceuticals4.0577 of 5 stars$1.54+3.4%$8.60+458.4%-82.8%$246.44M$351.41M-51.33220Analyst Revision Remove Ads Related Companies and Tools Related Companies Celldex Therapeutics Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Innoviva Alternatives Myriad Genetics Alternatives Verastem Alternatives Emergent BioSolutions Alternatives Vanda Pharmaceuticals Alternatives Ironwood Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
